Takeda Pharmaceutical Company Limited (BVMF:TAKP34)
Brazil · Delayed Price · Currency is BRL 93.24
-0.45 (-0.48%)
At close: Feb 6, 2026
Revenue Breakdown
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Gastroenterology Revenue (Pre-FY2023 Reporting) | - | - | 1.22T | |||||||||||
Gastroenterology Revenue (Pre-FY2023 Reporting) Growth | - | - | 11.12% | |||||||||||
Rare Hematology Revenue | - | - | 305.30B | |||||||||||
Rare Hematology Revenue Growth | - | - | 0.19% | |||||||||||
Rare Genetics and Other Revenue | - | - | 465.40B | |||||||||||
Rare Genetics and Other Revenue Growth | - | - | 11.15% | |||||||||||
Total Rare Diseases Revenue (Pre-FY2023 Reporting) | - | - | 770.70B | |||||||||||
Total Rare Diseases Revenue (Pre-FY2023 Reporting) Growth | - | - | 6.53% | |||||||||||
PDT Immunology Revenue (Pre-FY2023 Reporting) | - | - | 818.57B | |||||||||||
PDT Immunology Revenue (Pre-FY2023 Reporting) Growth | - | - | 20.65% | |||||||||||
Oncology Revenue (Pre-FY2023 Reporting) | - | - | 462.36B | |||||||||||
Oncology Revenue (Pre-FY2023 Reporting) Growth | - | - | 5.38% | |||||||||||
Neuroscience Revenue (Pre-FY2023 Reporting) | - | - | 627.01B | |||||||||||
Neuroscience Revenue (Pre-FY2023 Reporting) Growth | - | - | -1.68% | |||||||||||
Other Product Revenue (Pre-FY2023 Reporting) | - | - | 368.91B | |||||||||||
Other Product Revenue (Pre-FY2023 Reporting) Growth | - | - | -18.85% | |||||||||||
Revenue (Total) | 4.52T | 4.58T | 4.26T | |||||||||||
Revenue (Total) Growth | -1.39% | 7.45% | 5.87% |
Revenue Breakdown 2
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
GI Revenue (Post-FY2024 Reporting) | 1.40T | 1.36T | 1.22T | |||||||||||
GI Revenue (Post-FY2024 Reporting) Growth | 2.89% | 11.58% | 11.12% | |||||||||||
Rare Diseases Revenue (Post-FY2024 Reporting) | 748.20B | 752.82B | 688.42B | |||||||||||
Rare Diseases Revenue (Post-FY2024 Reporting) Growth | -0.61% | 9.35% | 7.60% | |||||||||||
PDT Revenue (Post-FY2024 Reporting) | 1.04T | 1.03T | 903.70B | |||||||||||
PDT Revenue (Post-FY2024 Reporting) Growth | 0.63% | 14.27% | 18.39% | |||||||||||
Oncology Revenue (Post-FY2024 Reporting) | 568.70B | 560.43B | 462.36B | |||||||||||
Oncology Revenue (Post-FY2024 Reporting) Growth | 1.48% | 21.21% | 5.38% | |||||||||||
Vaccines Revenue | 60.50B | 55.41B | 50.36B | |||||||||||
Vaccines Revenue Growth | 9.18% | 10.04% | -35.99% | |||||||||||
Neuroscience Revenue (Post-FY2024 Reporting) | 423.80B | 565.82B | 627.01B | |||||||||||
Neuroscience Revenue (Post-FY2024 Reporting) Growth | -25.10% | -9.76% | -1.68% | |||||||||||
Other Product Revenue (Post-FY2024 Reporting) | 228.00B | 257.39B | 315.70B | |||||||||||
Other Product Revenue (Post-FY2024 Reporting) Growth | -11.42% | -18.47% | -15.29% | |||||||||||
Revenue (Total) | 4.52T | 4.58T | 4.26T | |||||||||||
Revenue (Total) Growth | -1.39% | 7.45% | 5.87% |
Revenue by Geography
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Japan Revenue | 433.20B | 418.46B | 451.39B | |||||||||||
Japan Revenue Growth | 3.52% | -7.29% | -11.85% | |||||||||||
United States Revenue | 2.21T | 2.38T | 2.20T | |||||||||||
United States Revenue Growth | -7.03% | 8.38% | 4.37% | |||||||||||
Europe and Canada Revenue | 1.09T | 1.06T | 966.84B | |||||||||||
Europe and Canada Revenue Growth | 3.51% | 9.14% | 14.74% | |||||||||||
Latin America Revenue | 236.00B | 235.85B | 198.10B | |||||||||||
Latin America Revenue Growth | 0.06% | 19.05% | 23.52% | |||||||||||
China Revenue | 198.90B | 191.74B | 174.84B | |||||||||||
China Revenue Growth | 3.73% | 9.66% | 15.81% | |||||||||||
Asia (ex-Japan & China) Revenue | 96.90B | 99.39B | 86.38B | |||||||||||
Asia (ex-Japan & China) Revenue Growth | -2.51% | 15.07% | 16.67% | |||||||||||
Asia (ex-Japan) Revenue | 295.80B | 291.13B | 261.22B | |||||||||||
Asia (ex-Japan) Revenue Growth | 1.60% | 11.45% | 16.09% | |||||||||||
Russia / CIS Revenue | 70.90B | 72.36B | 72.59B | |||||||||||
Russia / CIS Revenue Growth | -2.01% | -0.33% | -17.91% | |||||||||||
Other Geographic Revenue | 123.90B | 128.85B | 117.91B | |||||||||||
Other Geographic Revenue Growth | -3.84% | 9.28% | 23.88% | |||||||||||
Revenue (Other) | 53.50B | 1.00M | 1.00M | |||||||||||
Revenue (Total) | 4.52T | 4.58T | 4.26T | |||||||||||
Revenue (Total) Growth | -1.39% | 7.45% | 5.87% |
Updated Dec 31, 2025. Data Source: Fiscal.ai.